Skip to main content
Clinical Trials/NCT06507202
NCT06507202
Recruiting
Phase 4

Comparison of Remimazolam Versus Propofol-based General Anesthesia on Postoperative Quality of Recovery in Patients Undergoing Ambulatory Upper Airway Surgery: a Randomized Controlled Trial

Chung-Ang University Gwangmyeong Hospital1 site in 1 country116 target enrollmentJanuary 22, 2024

Overview

Phase
Phase 4
Intervention
Remimazolam
Conditions
Laryngeal Disease
Sponsor
Chung-Ang University Gwangmyeong Hospital
Enrollment
116
Locations
1
Primary Endpoint
Fit-for-discharge time
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to compare the effects of remimazolam and propofol on postoperative recovery time, complications, and safety in patients undergoing ambulatory upper airway surgery under general anesthesia.

Detailed Description

Patients scheduled for ambulatory upper airway (including nasal cavity, oral cavity, pharynx, larynx) surgery and who agree to participate in the study will be randomly assigned to the Remimazolam group and the Propofol group. In the Remimazolam group, general anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil. Once the surgery is completed, general anesthesia is recovered with flumazenil. In the Propofol group, general anesthesia is induced and maintained by continuous infusion of propofol and remifentanil using a target concentration controlled infusion method. In both groups, rocuronium is used for neuromuscular blokade, and sugammadex is used for reversal of neuromuscular blockade. When the surgery is completed, recovery time, occurrence of adverse events, and anesthesia recovery indicators are examined in 3 stages: in the operating room, while staying in the post-anesthesia care unit(PACU), and while staying in the day surgery center.

Registry
clinicaltrials.gov
Start Date
January 22, 2024
End Date
March 22, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Chung-Ang University Gwangmyeong Hospital
Responsible Party
Principal Investigator
Principal Investigator

Se-Hee Min

Assistant professor

Chung-Ang University Gwangmyeong Hospital

Eligibility Criteria

Inclusion Criteria

  • Adult patients (age 19 or older) undergoing ambulatory upper respiratory tract (nasal cavity, oral cavity, pharynx, larynx) surgery under general anesthesia
  • American Society of Anesthesiologists physical class classification I, II, and III

Exclusion Criteria

  • Patients who refused to participate in the study
  • Pregnant patients
  • Patients with a history of hypersensitivity to drugs or additives used during surgery
  • Patients with acute narrow-angle glaucoma
  • Alcohol or drug dependent patients
  • Patients with Child-Pugh class C liver dysfunction

Arms & Interventions

Remimazolam group

General anesthesia is induced by continuously injecting remimazolam (6 mg/kg/h) and remifentanil (2-6 ng/ml, target concentration controlled infusion) through an infusion pump. Afterwards, when the patient loses consciousness, rocuronium 0.6 mg/kg is injected for endotracheal intubation, and anesthesia is maintained with remimazolam (1-2 mg/kg/hr) and remifentanil after endotracheal intubation. When the surgery is completed, all anesthetic drugs being administered are stopped, and general anesthesia is terminated with flumazenil and sugammadex.

Intervention: Remimazolam

Propofol group

General anesthesia is induced by continuously injecting propofol (2-6 mg/ml, target concentration controlled injection) and remifentanil (2-6 ng/ml, target concentration controlled injection) using a TCI infusion pump. Afterwards, when the patient loses consciousness, rocuronium 0.6mg/kg is injected for endotracheal intubation, and anesthesia is maintained with propofol and remifentanil after endotracheal intubation. When the surgery is completed, all anesthetic drugs being administered are stopped, and general anesthesia is terminated through sugammadex.

Intervention: Propofol

Outcomes

Primary Outcomes

Fit-for-discharge time

Time Frame: 15 minutes after surgery

Evaluated on a scale of 0 to 10 through the Modified Post Anesthetic Discharge Scoring System (MPADSS); a score of 9 or higher meets the discharge criteria.

Secondary Outcomes

  • postanesthetic care unit (PCAU) stay time, Day surgery center stay time(5 minutes)
  • Incidence of adverse events(6 hours)
  • Postoperative pain score(6 hours)
  • Time to eye opening, time to extubate, time to postanesthetic care unit (PACU) transfer(1 minute)
  • modified Observer's Alertness/Sedation Scale (MOAA/S) at PACU arrival(30 minutes)
  • modified Aldrete score at PACU arrival(30 minutes)

Study Sites (1)

Loading locations...

Similar Trials